BridgeBio Pharma (BBIO) Shares Outstanding (Diluted Average) (2020 - 2026)

BridgeBio Pharma's Shares Outstanding (Diluted Average) history runs 7 years deep, the most recent figure standing at $194.8 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Diluted Average) rose 2.44% year-over-year to $194.8 million; the TTM figure through Mar 2026 stood at $194.8 million (up 2.44% YoY), while the FY2025 annual figure was $191.5 million, up 2.93% from the prior year.
• Shares Outstanding (Diluted Average) came in at $194.8 million for Q1 2026 at BridgeBio Pharma, up from $191.5 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $194.8 million in Q1 2026 to a low of $145.9 million in Q1 2022.
• A 5-year average of $171.7 million and a median of $178.7 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
• Across the five-year window, Shares Outstanding (Diluted Average) grew 2.16% in 2022 and gained 17.07% in 2024, its largest moves.
• BridgeBio Pharma's Shares Outstanding (Diluted Average) stood at $147.5 million in 2022, then advanced by 10.39% to $162.8 million in 2023, then advanced by 14.3% to $186.1 million in 2024, then rose by 2.93% to $191.5 million in 2025, then advanced by 1.7% to $194.8 million in 2026.
• According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods registered $194.8 million, $191.5 million, and $191.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison